DrugNews: Study Suggests More Complications Reported With Byetta

Share Article

http://www.DrugNews.net is the web’s premier source for prescription drug warnings, research, side effects and legal news. Visit the DrugNews Center today.

byetta lawsuit
The resource center has added warnings about a possible Byetta link to cancer. A 2011 study from UCLA suggested the drug could increase the risk of pancreatic cancer and thyroid cancer.

The diabetes drug resource center at DrugNews.net is announcing updated information for patients taking the medication Byetta. A recent study suggests more patients report serious complications related to Byetta than with other GLP-1 diabetes medications*.

DrugNews is a free service offering the latest information on recalls, safety alerts, research and litigation news to those patients taking popular prescription drugs. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.

Byetta is a popular injectable-type medication sold by Bristol-Myers Squibb, which is prescribed to those with type-II diabetes to lower blood sugar levels**.

The resource center has added warnings about a possible Byetta link to cancer. A 2011 study from UCLA suggested the drug could increase the risk of pancreatic cancer and thyroid cancer***. This year, the Journal for the American Medical Association also advised that drugs like Byetta can double the risk of pancreatitis, a major risk factor for pancreatic cancer****.

Now, DrugNews has learned of a case study by the Institute for Safe Medication Practices, which found that, of 1,069 diabetes drug pancreatitis, pancreatic cancer, thyroid cancer or hypersensitivity cases reported to the FDA in 2012, 612 were linked to Byetta*.

Unfortunately, the FDA recently advised that the evidence is insufficient right now to show diabetes drugs like Byetta are associated with higher cancer rates or to require changes to product labels*****.

Due to the number of patients filing a Byetta lawsuit alleging cancer, the Judicial Panel on Multidistrict Litigation is deciding whether to consolidate cases to a special federal court. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, United States Judicial Panel on Multidistrict Litigation).

Anyone affected by cancer after taking Byetta is encouraged to visit the DrugNews center or speak with a lawyer about their legal options. However, DrugNews only recommends lawyers who have already handled these complex Byetta lawsuits.

For more information on the research, side effects and litigation news related to Byetta and other drugs, or to speak with a lawyer, visit http://www.DrugNews.net.

*ISMP QuarterWatch April, 2013.ismp.org/QuarterWatch/pdfs/2012Q3.pdf
**Bloomberg, 2/25/13; bloomberg.com/news/2013-02-25/merck-bristol-diabetes-drugs-linked-to-pancreatitis-risk.html
***Gastroenterology, July 2011; ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf
****JAMA Internal Medicine, 2/25/13; archinte.jamanetwork.com/article.aspx?articleid=1656537
*****Pharmalive 7/30/13; pharmalive.com/fda-decides-no-risk-of-pancreatic-cancer-with-diabetes-drugs

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Patient Advocate
DrugNews
888-987-4866
Email >
Visit website